Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

2017 ESMO Congress
Tweet this page

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).

Advertisement

Advertisement



Advertisement